Advances in Cancer Immunotherapy™ (ACI™-FL)

Purpose

Specifically designed for clinical oncologists and the entire unit of care involved in treating cancer patients with immunotherapy, these introductory, CME-certified programs will provide an understanding of basic immunology principles in the clinical application and management of cancer immunotherapy and discuss emerging drugs and concepts in the cancer immunotherapy field.

Presented by leading authorities in tumor immunology and cancer immunotherapy, these programs will facilitate understanding of 1) the underlying principles of tumor immunology and immunotherapy, 2) the clinical indications for cancer immunotherapy and appropriate selection of patients, 3) patient management, and 4) the therapeutic effectiveness of immunotherapy to ultimately improve patient outcomes.

Attendees can also take advantage of the opportunity for professional networking that will promote collaboration and scientific exchange with experts, clinical oncologists and other health care providers from the surrounding community.

Intended Audience

The target audience for these programs includes clinical oncologists, those involved in patient care, early career individuals, allied health professionals, and patient advocates who wish to learn principles of tumor immunology and immunotherapy, as well as improve their ability to select patients for immunotherapy and provide state-of-the-art clinical management for their patients.

Session Topics

Adjuvant Immunotherapy for High-Risk Melanoma: Where Have We Been and Where Are We Going?
Adoptive T Cell Immunotherapy for Metastatic Melanoma
Checkpoint Inhibitors for Metastatic Melanoma
Combination Immunotherapies for Metastatic Melanoma: What Agents and When?
Current Status of Immunotherapy for Kidney, Prostate and Bladder Cancer, Including Vaccines
Dual Role of the Immune System in Protection and Pathogenesis
Immune Escape – Targeting Immune Suppression as a Therapeutic Option
Immunology 101 for the Non-Immunologist
Immunotherapies for Lung Cancer
Novel Gene Expression Signatures with Pathologic Correlates of Immune Reactivity
Oncolytic Virus Therapy in Cancer Immunotherapy: Brain Tumors
Overview of Immune-Related Biomarkers and Companion Diagnostics
Radiation and Immune Therapy

Educational Objectives

Upon completion of this program, the participants will be able to:

Interpret the key principles of tumor immunology and immunotherapy
Analyze recent research and clinical applications of cytokines, cancer vaccines, T cell checkpoint inhibitors, adoptive immunotherapy and biomarkers
Participate in scientific exchange with local colleagues, potential collaborators, and subject matter experts on research and clinical application of cancer immunotherapy
Implement cancer immunotherapy treatments into clinical practice more effectively through a sound understanding of how they work, the clinical management of patients, and the potential to improve patient outcomes with tumor immunotherapy

+ show speakers and program
Program Schedule

(as of July 18, 2014)

Presentations include allotted time for Audience Response System (ARS) assisted audience interaction as well as general question and answer time.

8:00 am - 8:10 am Welcome and Introductions
James J. Mulé, PhD – Moffitt Cancer Center

Session #1: Principles of Tumor Immunology with AMA PRA Category 1 Credits™

8:10 am - 8:35 am Immunology 101 for the Non-Immunologist
Shari A. Pilon-Thomas, PhD – Moffitt Cancer Center

8:35 am - 9:00 am Dual Role of the Immune System in Protection and Pathogenesis
Keith L. Knutson, PhD – Vaccine & Gene Therapy Institute of Florida

9:00 am - 9:25 am Immune Escape – Targeting Immune Suppression as a Therapeutic Option

9:25 am - 9:40 am Break

Session #2: Immunotherapy for Melanoma with AMA PRA Category 1 Credits™

9:40 am - 10:05 am Checkpoint Inhibitors for Metastatic Melanoma
Jose Lutzky, MD, FACP – Mount Sinai Medical Center

10:05 am - 10:30 am Adoptive T Cell Immunotherapy for Metastatic Melanoma

10:30 am - 10:55 am Adjuvant Immunotherapy for High-Risk Melanoma: Where Have We Been and Where Are We Going?
Vernon K. Sondak, MD – Moffitt Cancer Center

10:55 am - 11:20 am Combination Immunotherapies for Metastatic Melanoma: What Agents and When?

11:20 am - 11:50 am Panel Discussion

11:50 am - 12:45 pm Lunch

Session #3: Immunotherapy for Other Solid Tumors and Immune-Related Biomarkers with AMA PRA Category 1 Credits™

12:45 pm - 1:10 pm Oncolytic Virus Therapy in Cancer Immunotherapy: Brain Tumors

1:10 pm - 1:35 pm Immunotherapies for Lung Cancer

1:35 pm - 2:00 pm Radiation and Immune Therapy

2:00 pm - 2:15 pm Break

2:15 pm - 2:40 pm Overview of Immune-Related Biomarkers and Companion Diagnostics

2:40 pm - 3:00 pm Novel Gene Expression Signatures with Pathologic Correlates of Immune Reactivity

3:00 pm - 3:20 pm Current Status of Immunotherapy for Kidney, Prostate and Bladder Cancer, Including Vaccines
Johannes Vieweg, MD, FACS – University of Florida

3:20 pm - 3:45 pm Panel Discussion

3:45 pm - 4:00 pm Closing Remarks
James J. Mulé, PhD – Moffitt Cancer Center and Vernon K. Sondak, MD – Moffitt Cancer Center



5 Dec - 5 Dec 2014
Tampa
United States of America
meeting website